BKM120+Abiraterone Acetate for Metastatic CRPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01741753
Recruitment Status : Terminated (Due to slow accrual the supllier of BKM120 requested that we cease further enrollment.)
First Posted : December 5, 2012
Last Update Posted : March 23, 2018
Information provided by (Responsible Party):
Glenn Bubley, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 29, 2014
  Actual Study Completion Date : September 1, 2016